I presume the comparative safety study is complete. The Company indicated that ".....if completed successfully......procure approval from the Israeli Health Ministry for the production and export of our tablet".

So the question is: how did we do?

Of course, there is always a lot of background tabulations and review but I would expect, if the study was successful, a SEC filing may be warranted or at least a note to the shareholders.